More Cynata Therapeutics Limited news
Cynata Therapeutics LimitedASX: CYP

Cynata Advances to Pre-IND Meeting with US FDA

Apr 18, 2017 at 11:31 PM EDT · Issued by Cynata Therapeutics Limited

Filed with ASX · Apr 18, 2017 at 11:31 PM EDT · 2 pages · English

On 6ix: 6ix.com/news/cynata-advances-to-pre-ind-meeting-with-us-fda

Cynata Therapeutics Limited on 6ix

Story so far

  • CYP Advances Development of Cymerus for Treatment of AsthmaMar 2, 2017

Earlier from Cynata Therapeutics

  • CYP Files for New Patent for Oncology ApplicationsApr 12, 2017
  • CYP in Collaboration on Acute Respiratory Distress SyndromeApr 10, 2017
  • Cynata Partner apceth GmbH & Co Completes Cymerus EvaluationMar 30, 2017
  • CYP Advances Development of Cymerus for Treatment of AsthmaMar 1, 2017
  • Final GvHD Preclinical Report Confirms Treatment BenefitFeb 5, 2017

Later from Cynata Therapeutics

  • March 2017 Quarterly ReportApr 26, 2017
  • Treatment Commences in Cynatas World First Clinical TrialMay 16, 2017
  • United States Patent for Core Cynata TechnologyJun 19, 2017
  • Cynata Files New Patent Application for Cymerus in OncologyJun 20, 2017
  • CYP MSC Data in Asthma Model Published in Sceintific JournalJun 22, 2017
All Cynata Therapeutics news releases↗

Follow Cynata Therapeutics into a list and get an email when it puts out news.

Follow Cynata Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer